After seven years of debate, and 19 formal rounds of negotiations, the Trans-Pacific Partnership was agreed in October this year. Its IP provisions, which are among the most controversial, will have an impact on pharmaceutical protection, copyright, trade marks, geographical indications and enforcement, among other areas. Peter Leung provides a summary of the main points and over the following pages we look at the impact country-by-country
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices